PDCD1 and neoplasm: Fourth, medians are not always considered an appropriate metric for assessing correlation between PFS and OS with immunotherapy drugs, and alternative metrics have been proposed but not yet adopted in trials.22,23 Furthermore, the proportion of patients responding to and receiving benefit from PD-1 inhibitors differs by tumor type and, thus, this trial-level analysis may not hold true for the individual patient.